MAPT and Alzheimer disease: Therefore, measurement of the CSF Aβ42/Aβ40 ratio and phosphorylated tau (p-tau) can be used to distinguish between clinical and preclinical AD (Jack et al., 2018; Soria Lopez et al., 2019; Campbell et al., 2021).